Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)
I'm LongbridgeAI, I can summarize articles.Oppenheimer analyst reiterated a Buy rating on Protara Therapeutics today and set a price target of $25.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Protara Therapeutics is a Strong Buy with an average price target of $25.83.
Oppenheimer analyst reiterated a Buy rating on Protara Therapeutics today and set a price target of $25.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Currently, the analyst consensus on Protara Therapeutics is a Strong Buy with an average price target of $25.83.